bullish
Concord Biotech Pre-IPO - Sales Have Been Growing but Watch Out for Its High Concentration Risk
393 Views30 Jan 2023 11:03
Concord Biotech Ltd (658823Z IN) is looking to raise around US$250m in its upcoming India IPO. Concord is an India-based biopharma firm, which develops and manufactures fermentation-based APIs.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 13-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (19th Feb 2023) - Rakuten Bank, ZJLD, REPT, Link REIT, SoCar, Ryman, Indigo, ESR, Oasis19 Feb 2023
- ECM Weekly (12th Feb 2023) - Hesai, Oasis, Mankind, Greatpower, Ruipeng, CATL, Nissan/Renault12 Feb 2023
- ECM Weekly (5th Feb 2023) - Adani, Pertamina, Hesai, Ruipeng Pet, Concord, Oasis, Flight Centre05 Feb 2023
- Concord Biotech Pre-IPO Tearsheet24 Aug 2022
x